Echo Therapeutics (ECTE) Closes 3.2M Offering at 95c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
Echo Therapeutics (ECTE) Underwriters Exercise Full Overallotment in 3.2M Offering
December 26, 2012 4:19 PM ESTEcho Therapeutics, Inc. (Nasdaq: ECTE) announced the full exercise of the over-allotment option granted to the underwriters to purchase 480,000 additional common shares, at a public offering price of $0.95 per share, in connection with its previously announced underwritten public offering of 3,200,000 shares of common stock,... More
Echo Therapeutics (ECTE) Prices 3.2M Offering at 95c/Share
December 21, 2012 7:06 AM ESTEcho Therapeutics, Inc. (Nasdaq: ECTE) today announced the pricing of a previously announced underwritten public offering of 3,200,000 shares of its common stock, offered at a price to the public of $0.95 per share. The gross proceeds to Echo from this offering are expected to be approximately $3.0... More
Echo Therapeutics (ECTE) Announces Common Offering
December 20, 2012 4:26 PM ESTEcho Therapeutics, Inc. (Nasdaq: ECTE) intends to offer for sale its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be... More
